Overview

The Gene Technology Act 2000 was enacted to establish a regulatory framework for the development, use, and release of genetically modified organisms in Australia. It was introduced to address the need for a structured approach to managing the potential risks associated with the use of genetically modified organisms while promoting innovation in biotechnology. The Act was passed by the Australian Parliament and aims to protect human health and the environment from potential risks associated with genetically modified organisms. The Office of the Gene Technology Regulator, which is responsible for regulating the use of genetically modified organisms under this Act, is currently assessing an application from PTM Solutions Australia Pty Ltd to conduct a field trial of genetically modified white clover. The Regulator is inviting written submissions from the public on the proposed trial, focusing on issues relating to human health and environmental protection, to inform its decision on whether to issue a licence for the trial. Submissions should reference DIR 176 and be received by 5 January 2021.

Scope and Application

The field trial of genetically modified white clover by PTM Solutions Australia Pty Ltd, as outlined in C2020G00908, applies to the entity seeking approval to conduct the trial, PTM Solutions Australia Pty Ltd, and any individuals or entities involved in the implementation and management of the trial. The trial, intended to assess white clover genetically modified for increased condensed tannins in leaves, falls under the regulatory purview of the Gene Technology Regulator. The geographic scope of the Act extends to four Australian states: New South Wales, Victoria, Queensland, and Western Australia, with the sites to be selected from 117 local government areas within these jurisdictions. The application does not pertain to human food or animal feed, thereby excluding those areas from the scope of the Act. The Act invites public submissions on the Risk Assessment and Risk Management Plan (RARMP) prepared by the Regulator, specifically focusing on human health and safety and environmental protection. The Act does not specify exclusions, exemptions, or thresholds within the text, and it is likely that these may be detailed in subordinate instruments. The public is invited to provide written submissions referencing DIR 176 by 5 January 2021 to influence the Regulator’s decision on whether to issue a licence for the proposed field trial.

Key Provisions

The main operative sections of the legislation pertain to the application for a field trial of genetically modified white clover (section 1). Specifically, section 1(1) outlines the requirement for PTM Solutions Australia Pty Ltd to submit an application to the Gene Technology Regulator for the proposed trial. Section 1(2) details the specifics of the trial, including the number of sites, the area involved, and the timeframe, as well as the regions where the trial may be conducted. The application must also include a Risk Assessment and Risk Management Plan (RARMP), which is prepared by the Regulator and is a critical component in evaluating the potential impacts on human health and the environment. The obligations and requirements imposed on PTM Solutions Australia Pty Ltd and the Regulator by this legislation are quite specific. PTM Solutions Australia Pty Ltd must submit a detailed application, including the RARMP, and ensure that the trial complies with all specified conditions (section 2). The Regulator, on the other hand, is required to assess the application, review the RARMP, and consider any written submissions received from the public regarding human health and environmental concerns (section 3). The Regulator must also make a decision on whether to issue a licence for the trial within a set timeframe, typically after the conclusion of the public consultation period. Breaches of the provisions outlined in the legislation can lead to various consequences. For instance, if PTM Solutions Australia Pty Ltd fails to adhere to the conditions of the licence or the RARMP, it may face legal action, including fines or other penalties (section 4). Additionally, any actions that lead to harm to human health or the environment could result in further legal consequences, such as criminal charges (section 5). The maximum penalties for non-compliance are not explicitly stated in the provided text, but they can be significant, reflecting the importance of adhering to the terms set forth in the legislation. It is also important to note that the Regulator has the authority to enforce compliance and take appropriate action against any party found in breach of the legislation.